Giavina-Bianchi Júnior, Pedro Francisco 
; Cua, E; Risso, K; Mondain, V; Vissian, A; Joie, C; Pouletty, P; Gineste, P; Ehrlich, H. J; Kalil Filho, Jorge Elias
Source: Journal of allergy and clinical immunology: global. Unidade: FM
Subjects: CORONAVIRUS, COVID-19, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIAVINA-BIANCHI JÚNIOR, Pedro Francisco et al. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial. Journal of allergy and clinical immunology: global, v. 2, n. 4, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58602. Acesso em: 03 nov. 2024.APA
Giavina-Bianchi Júnior, P. F., Cua, E., Risso, K., Mondain, V., Vissian, A., Joie, C., et al. (2023). ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial. Journal of allergy and clinical immunology: global, 2( 4). doi:10.1016/j.jacig.2023.100140NLM
Giavina-Bianchi Júnior PF, Cua E, Risso K, Mondain V, Vissian A, Joie C, Pouletty P, Gineste P, Ehrlich HJ, Kalil Filho JE. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial [Internet]. Journal of allergy and clinical immunology: global. 2023 ; 2( 4):[citado 2024 nov. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58602Vancouver
Giavina-Bianchi Júnior PF, Cua E, Risso K, Mondain V, Vissian A, Joie C, Pouletty P, Gineste P, Ehrlich HJ, Kalil Filho JE. ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial [Internet]. Journal of allergy and clinical immunology: global. 2023 ; 2( 4):[citado 2024 nov. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58602
